AtaiBeckley Inc (ATAI)

AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets

AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026...

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

Three $20,000 grants open to non-profit, mission-driven organizations working across community support...

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a...

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026VLS-01...

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a...

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of...

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking...

Form 144 - Report of proposed sale of securities

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a...

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in...

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions Canada NewsWire VANCOUVER, BC...

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026...

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression

Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term...

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments Canada NewsWire...